Technology | April 11, 2013

ICU Medical Launches CardioFlo Minimally Invasive Hemodynamic Monitoring Sensor System

CardioFlo is shown in clinical testing to provide accurate, reliable and cost-effective hemodynamic monitoring

April 11, 2013 — ICU Medical Inc. has launched the CardioFlo hemodynamic monitoring sensor system. CardioFlo is a minimally invasive hemodynamic monitoring sensor system that, when used with an existing arterial catheter and connected to an Edwards Lifesciences Vigileo monitor, provides accurate and reliable hemodynamic monitoring data and an average of 40 percent cost savings over the Edwards Lifesciences FloTrac sensor.

CardioFlo facilitates the real-time assessment of hemodynamic and cardiovascular status, helping guide clinical decision-making and effective management of critically ill patients. In clinical testing, the level of agreement between the hemodynamic data provided by the Edwards Lifesciences FloTrac and the ICU Medical CardioFlo sensor systems was within 1 percent. As a result, CardioFlo provides a cost-effective alternative to the FloTrac sensor without sacrificing accuracy or reliability.

CardioFlo is available with the SafeSet closed blood sampling system, which allows clinicians to reduce blood discard waste during diagnostic phlebotomy by reinfusing it to the patient.

For more information: www.icumed.com

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init